Who
Carlos Campoy
Director
Company insider
Files Form 4 as: Director, Zymeworks; Chief Financial Officer, CytomX Therapeutics; Chief Financial Officer, Alder Biopharmaceuticals.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $9,069
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 12 Dec 2018
- Last trade
- 12 Jan 2026
- Last filed
- 12 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 10 Dec 2024filed 12 Dec 2024 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 7 Dec 2023filed 8 Dec 2023 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 30 Jun 2023filed 30 Jun 2023 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 16 Mar 2023filed 20 Mar 2023 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,4611,748 at $1.98 | filing |
| 20 Jul 2022filed 21 Jul 2022 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,6083,949 at $1.42 | filing |
| 19 Jul 2022filed 21 Jul 2022 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 2 Feb 2022filed 4 Feb 2022 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 2 Feb 2022filed 4 Feb 2022 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 24 Oct 2021filed 26 Oct 2021 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 24 Oct 2021filed 26 Oct 2021 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 31 May 2021filed 8 Jun 2021 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | $20K3,320 at $6.09 | filing |
| 26 Feb 2021filed 2 Mar 2021 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 30 Nov 2020filed 7 Dec 2020 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code A | $20K3,101 at $6.39 | filing |
| 23 Mar 2020filed 25 Mar 2020 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —270,000 at $0.00 | filing |
| 12 Dec 2018filed 14 Dec 2018 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —270,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.